Pieris Pharma (PIRS) Reports In-Line Q2 Loss

August 10, 2016 5:01 PM EDT
Get Alerts PIRS Hot Sheet
Trade PIRS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Pieris Pharma (NASDAQ: PIRS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment